~~<i id='6AA75EA5D1'><strike id='6AA75EA5D1'><tt id='6AA75EA5D1'><pre id='6AA75EA5D1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：hotspot 2025-10-01 20:06:36 - browse：59134

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： President Biden's budget: Here's what you might have missed

hotspot

focus

Wikipedia

hotspot

knowledge

focus

AdobeForyears,theplaybookformanycompaniesthatwantedtomarketdigitaltherapeuticswasstupidsimple:Sellit

WSS

Medicare Advantage today, explained in one chart

Humana cuts profit projections as Medicare Advantage costs soar

Pushing for an NIH office for post

FDA advisers back CAR

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Ebola: Gilead Sciences antiviral shows promise as new treatment

focus

Wikipedia

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

RaDonda Vaught links Vanderbilt hospital issues to patient death

Guidelines to prevent youth baseball injuries need more muscle

Ebola: Gilead Sciences antiviral shows promise as new treatment

Virginia high school admissions case could be legal follow

Pushing for an NIH office for post

State Dept. review finds Biden bears some blame for Afghanistan failures

Steward Health Care Massachusetts hospitals face fiscal disaster

Virginia high school admissions case could be legal follow

FDA advisers back CAR

focus

Steward Health Care Massachusetts hospitals face fiscal disaster

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

The surgeon had a dilemma only a Nazi medical text could resolve

FDA clears AI tool for detecting skin cancer

Copay coupons to count toward deductibles, after Biden court move

The surgeon had a dilemma only a Nazi medical text could resolve

Wikipedia

hotspot

knowledge

focus